| EDIT Shares Outstanding History Table | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Below is a table of the EDIT shares outstanding history going back to 2/3/2016:
Also see: EDIT Market Cap History EDIT YTD Return |
EDIT Shares Outstanding History — Editas Medicine Share Count Over Time
As of 4/29/2026 Editas Medicine has 97.91 million EDIT shares outstanding. Investors often track the EDIT shares outstanding history to compare shareholder return trends against the change in share count over time.
This page shows EDIT share count trends over time, with 43 historical shares outstanding datapoints presented, dating back to 2/3/2016.
| EDIT Shares Outstanding History Chart | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
EDIT Historical Shares Outstanding: +10.36% CAGR 
Mouse over chart for data details
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EDIT Stock Price Chart |
| About Editas Medicine Inc |
| Editas Medicine, Inc. is a clinical-stage genome editing company. Co. is focused on developing potentially transformative genomic medicines to treat a broad range of serious diseases. It has developed a proprietary gene editing platform based on CRISPR technology. CRISPR uses a protein- ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 (Cas9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1), bound to a guide ribonucleic acid (RNA) molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence. We show 43 historical shares outstanding datapoints in our coverage of EDIT's shares outstanding history. Understanding the changing numbers of EDIT shares outstanding — and comprehending the concept of differing number of shares outstanding in general comparing companies like EDIT versus peers — is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies. Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history. With this page we aim to empower investors researching EDIT by allowing them to research EDIT shares outstanding history as well as any other stock in our coverage universe. |
| EDIT Current Stock Quote |
Quotes delayed 20 minutes  Free EDIT Email Alerts:
Get Dividend Alerts 
Get SEC Filing Alerts
|
| Video: Shares Outstanding Importance | |
|
Video: Shares Outstanding Importance
| EDIT Share Performance |
| Shares Outstanding Peers |
| Editas Medicine (EDIT) is categorized under the Healthcare sector; to help you further research historical shares outstanding numbers, below are some other companies in the same sector:
EGLT Shares Outstanding History EGRX Shares Outstanding History EHAB Shares Outstanding History EHC Shares Outstanding History EIDX Shares Outstanding History EIGR Shares Outstanding History EKSO Shares Outstanding History ELAB Shares Outstanding History ELAN Shares Outstanding History ELDN Shares Outstanding History More Healthcare companies » |
EDIT Shares Outstanding History | www.SharesOutstandingHistory.com | Copyright © 2017 - 2026, All Rights Reserved
Nothing in SharesOutstandingHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you
agree to the following Full Disclaimer & Terms of Use and
Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at
least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.
